From the Department of Plastic and Reconstructive Surgery, the First Affiliated Hospital of Zhengzhou University.
Plast Reconstr Surg. 2022 Nov 1;150(5):979e-986e. doi: 10.1097/PRS.0000000000009645. Epub 2022 Aug 22.
Benign parotid hypertrophy makes the earlobe area appear swollen and weakens the lateral facial contour and aesthetics. Efficacious treatment for benign parotid hypertrophy is not available. The authors evaluated the efficacy and safety of botulinum toxin type A for benign parotid hypertrophy treatment.
Thirty-six participants with benign parotid hypertrophy were enrolled and treated with botulinum toxin type A injection. After 6 months of follow-up, changes in the thickness and length of the superficial lobe of the parotid gland were assessed. Analyses of patient subgroups and image analyses were also undertaken to assess improvement.
Thirty-three participants completed this study. Superficial lobe of the parotid gland thickness was reduced significantly after botulinum toxin type A injection, but the longitudinal diameter of the parotid gland was not changed significantly ( p < 0.001 and p = 0.146, respectively). Subgroup analyses showed that the degree of parotid gland hypertrophy affected treatment efficacy and degree of improvement, but age and sex did not ( p < 0.001, p = 0.137, and p = 0.138, respectively). Image analyses showed improvement in the facial contour ( p < 0.05). Serious adverse reactions or complications were not observed.
Botulinum toxin type A can be used to treat benign parotid hypertrophy, reduce parotid gland volume, and improve the facial contour.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
良性腮腺肥大使耳垂区域看起来肿胀，并削弱了侧面部轮廓和美观。目前尚无有效的良性腮腺肥大治疗方法。作者评估了 A 型肉毒毒素治疗良性腮腺肥大的疗效和安全性。
36 名患有良性腮腺肥大的参与者被纳入并接受 A 型肉毒毒素注射治疗。在 6 个月的随访后，评估腮腺浅叶的厚度和长度的变化。还进行了患者亚组分析和图像分析，以评估改善情况。
33 名参与者完成了这项研究。A 型肉毒毒素注射后，腮腺浅叶厚度显著减少，但腮腺长径无明显变化（分别为 p<0.001 和 p=0.146）。亚组分析表明，腮腺肥大的程度影响治疗效果和改善程度，但年龄和性别没有影响（分别为 p<0.001、p=0.137 和 p=0.138）。图像分析显示面部轮廓得到改善（p<0.05）。未观察到严重不良反应或并发症。
A 型肉毒毒素可用于治疗良性腮腺肥大，减少腮腺体积，改善面部轮廓。
临床问题/证据水平：治疗性，IV。
